At the heart of the Oncopole of Toulouse, the CRCT, together with all its partners (institutional, academic, clinical, industrial, charities…), stimulates innovation in terms of research and teaching in the fight against cancer.
The CRCT is a joint Research Unit Inserm & University Toulouse III Paul Sabatier
3 research teams are also labelled by the CNRS
Researchers, clinicians and supports
PhD students and post-doctoral fellows
Immunotherapy is a treatment that aims to educate our immune system against cancer cells. This treatment resulted in a long-term response in patients with metastatic melanoma (40-60%) with in some cases total tumour regression. The challenge is now that the maximum...
Dendrogenin A (DDA) is a tumor suppressor mammalian cholesterol-derived metabolite and a new class of ligand of the Liver X receptor (LXR), which displays tumor cell differentiation. In human and mouse breast adenocarcinoma cells, DDA-induced cell differentiation was...
A collaboration in Toulouse, France, between Pierre Fabre Research Institute, the University Cancer Institute and the Cancer Research Center aims to collect and integrate data to improve and personalize immuno-therapies. Immunotherapies are imposing themselves as a...
Conférence CRCT : Dr Camille Lobry Institut Gustave Roussy, Paris : Non-coding genome and epigenetic regulation of transcription in leukemiaMarch 27 @ 11:00 - 12:00 at Salle C. Cazaux, CRCT
Conférence CRCT : Pr Angelo Parini – I2MC Toulouse : Sénescence cellulaire, fragilité, vieillissement: les enjeux des cohortes INSPIREMarch 6 @ 11:00 - 12:00 at Salle C. Cazaux, CRCT
Centre de Recherches en Cancérologie de Toulouse
2 avenue Hubert Curien
31037 TOULOUSE CEDEX 1 – FRANCE